← All peptides
warningBioGate · AMBERGrade B

AOD-9604 (hGH 176-191)

YLRIVQCRSVEGSCGF

Modified C-terminal fragment of hGH (residues 176-191); preclinically lipolytic but failed to demonstrate clinical weight loss in Phase 2 trials.

disulfide C7-C15tyrosine-extended hGH C-terminal fragment
MW
1815.13
Length
16aa
Posterior
68.7%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · disulfide C7-C15
PDA-V1 attestation

Cryptographic chain of custody.

Outer PDA hash
Inputs hash
Merkle root
TEE attestation
Protocol version
PDA-V1
Source
peptide-md
Model version
structure-fm-2026.04
Candidates emitted
5
Signed
2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with @peptide-md/verifier.
Verify this attestation →Download dossier (PDF)Compare with…
Real-world evidence

Cohort-attested outcomes.

Cohorts
6
Participants
459
Mean Δ
+1.09
Δ HRV ms (8-week) · 95% CI [0.64, 1.54]
IPNFT - Not minted

This peptide is not currently represented as an IPNFT. Cohort outcomes feed back into the unminted pool.

Citations

Source literature.

Grade C2001 · Endocrinology

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism

Heffernan M et al.

PMID 11796512